Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(1 year, 7 months from now) | |
US8946251 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(2 years from now) | |
US8658663 | SEBELA IRELAND LTD | Method of treating thermoregulatory disfunction with paroxetine |
Apr, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9393237 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(2 years from now) |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 28 June, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10166206 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) | |
US10166205 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) | |
US10729667 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) | |
US10695303 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) | |
US9161914 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) | |
US8778365 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(9 years from now) |
Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 June, 2013
Treatment: Treatment of fungal infections
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8486456 | SEBELA IRELAND LTD | Itraconazole compositions with improved bioavailability |
Oct, 2028
(5 years from now) |
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 29 April, 2010
Treatment: Onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(1 year, 7 months from now) |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 03 July, 2003
Treatment: NA
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic